Yuan Liang, Ping Wang, WeiminCi†. Clinical Perspective on the Use of Urine as a Tissue Surrogate in the Diagnosis of Genitourinary Diseases. Clinical chemistry, 2024;70(11):1303-1304

Neng-Bin Xie*; Min Wang*; Wei Chen*; Tong-Tong Ji ; Xia Guo; Fang-Yin Gang ; Yu-QiFeng; Yuan Liang†; Weimin Ci†; Bi-Feng Yuan†; Whole-Genome Sequencing of 5-Hydroxymethylcytosine at Base Resolution by Bisulfite-Free Single-Step Deaminationwith Engineered Cytosine Deaminase, ACS Central Science, 2023, 9(12): 2315-2325

Yuan Liang*; Yezhen Tan*; Bao Guan*; Bin Guo; Mancheng Xia; Juan Li; Yue Shi; YueShi; Qi Zhang; Di Liu; Xiaopeng Yang; Junfeng Hao; Yanqing Gong; MuhammadShakeel; Liqun Zhou†; Weimin Ci†; Xuesong Li†; Single-cell atlases link macrophagesand CD8(+) T-cell subpopulations to diseaseprogression and immunotherapy response inurothelial carcinoma, Theranostics, 2022, 12(18): 7745-7759

Zihui Yu*; Ziying Xu*; Yuan Liang*; Pengbin Yin; Yue Shi; Jiayi Yu; Junfeng Hao; TingWang; Weimin Ci†; Vitamin C Deficiency Causes Cell Type-Specific EpigeneticReprogramming and Acute Tubular Necrosis in a Mouse Model, Journal of the American Society of Nephrology, 2022, 33(3): 531-546

Juan Li*; Yuan Liang*; Jian Fan*; Chunru Xu*; Bao Guan; Jianye Zhang; Bin Guo; YueShi; Ping Wang; Yezhen Tan; Qi Zhang; Changwei Yuan; Yucai Wu; Liqun Zhou†;Weimin Ci† and Xuesong Li†; DNA methylation subtypes guiding prognostic assessmentand linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelialcarcinoma. BMC Medicine, 2022, 20(1)

Lu Huan*; Yuan Liang*; Guan Bao*; Shi Yue; Gong Yanqing; Li Juan; Kong Wenwen;Liu Jin; Fang Dong; Liu Libo; He Qun; Muhammad Shakeel; Li Xuesong†; Zhou Liqun†;Ci Weimin†; Aristolochic acid mutational signature defines the low-risk subtype in uppertract urothelial carcinoma, Theranostics, 2020, 10(10): 4323-4333